Fig. 1
From: CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Graphical representation of XMITTN. Two independent datasets were included, with the ADNI cohort as the training set and the Emory cohort as the independent test set. Within the ADNI cohort, 1000-fold cross validation is performed with each biomarker feature set (without or without C3 and FH) to determine which biomarker-ML combination results in internally validated separation between MCI and AD. The successful biomarker-ML combination is then tested in the test set through 1000-fold bootstrapping